Home › Cytokine Release Syndrome › Ohio
Cytokine Release Syndrome clinical trials in Ohio
3 studies for Cytokine Release Syndrome are looking for participants at sites in Ohio.
Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 8, 2026 · NCT07657312Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
RecruitingPhase 1
Ages 18 to 65 · All sexes · Updated Jun 25, 2026 · NCT06447376Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Oncology Hematology Care, Cincinnati
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT05972135From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.